


Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-797D27B7-31A6-48AD-BA2E-77005938668D\_4\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M32672\\_04\\_01](https://doi.org/10.31003/USPNF_M32672_04_01)  
DOI Ref: we9ul

© 2025 USPC  
Do not distribute

# Fenbendazole



$C_{15}H_{13}N_3O_2S$  299.35  
Carbamic acid, [5-(phenylthio)-1*H*-benzimidazol-2-yl]-, methyl ester;  
Methyl 5-(phenylthio)-2-benzimidazolecarbamate CAS RN®: 43210-67-9; UNII: 621BVT9M36.

**DEFINITION**  
Fenbendazole contains NLT 98.0% and NMT 101.0% of fenbendazole ( $C_{15}H_{13}N_3O_2S$ ), calculated on the dried basis.

**IDENTIFICATION**  
*Change to read:*

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: 197A, 197K, or 197M ▲ (CN 1-May-2020)

**ASSAY**

• **PROCEDURE**

**Sample:** 200 mg

**Analysis:** Dissolve the *Sample* in 30 mL of [glacial acetic acid](#), warming if necessary to effect solution. Allow to cool, and titrate with [0.1 N perchloric acid VS](#), determining the endpoint potentiometrically. Each mL of 0.1 N perchloric acid is equivalent to 29.94 mg of fenbendazole ( $C_{15}H_{13}N_3O_2S$ ).

**Acceptance criteria:** NLT 98.0%–101.0% on the dried basis

**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.3%

• **ORGANIC IMPURITIES**

**Solution A:** [Methanol](#), [acetic acid](#), and water (30:1:70)

**Solution B:** [Methanol](#), [acetic acid](#), and water (70:1:30)

**Mobile phase:** See [Table 1](#).

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|------------|----------------|----------------|
| 0          | 100            | 0              |
| 10         | 0              | 100            |
| 40         | 0              | 100            |
| 50         | 100            | 0              |

**Diluent:** [Methanol](#) and [hydrochloric acid](#) (99:1)

**System suitability stock solution:** 0.1 mg/mL each of [USP Fenbendazole RS](#) and [USP Mebendazole RS](#) in [methanol](#)

**System suitability solution:** 0.01 mg/mL each of [USP Fenbendazole RS](#) and [USP Mebendazole RS](#) from the *System suitability stock solution* in *Diluent*

**Standard stock solution A:** 0.025 mg/mL of [USP Fenbendazole RS](#) prepared as follows. Dissolve a weighed quantity of [USP Fenbendazole RS](#) in *Diluent* to obtain a solution with a known concentration of 5 mg/mL. Dilute 1.0 mL of this solution with [methanol](#) to 200.0 mL.

**Standard solution A:** 0.0125 mg/mL of [USP Fenbendazole RS](#) from *Standard stock solution A* in *Diluent*

**Standard stock solution B:** 0.1 mg/mL of [USP Fenbendazole Related Compound A RS](#) in [methanol](#)

**Standard solution B:** 0.01 mg/mL of [USP Fenbendazole Related Compound A RS](#) from *Standard stock solution B* in *Diluent*

**Standard stock solution C:** 0.1 mg/mL of [USP Fenbendazole Related Compound B RS](#) in [methanol](#)

**Standard solution C:** 0.01 mg/mL of [USP Fenbendazole Related Compound B RS](#) from *Standard stock solution C* in *Diluent*

**Sample solution:** Dissolve 5.0 mg/mL of Fenbendazole in *Diluent*.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 280 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 10 μL

#### System suitability

**Sample:** *System suitability solution*

[NOTE—The relative retention times for mebendazole and fenbendazole are about 0.85 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 1.5 between mebendazole and fenbendazole

#### Analysis

**Samples:** *Standard solution A*, *Standard solution B*, *Standard solution C*, and *Sample solution*

Calculate the percentages of fenbendazole related compound A and fenbendazole related compound B in the portion of Fenbendazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of each related compound from the *Sample solution*

$r_S$  = peak response of the corresponding related compound from *Standard solution B* or *Standard solution C*

$C_S$  = concentration of the corresponding related compound in *Standard solution B* or *Standard solution C* (mg/mL)

$C_U$  = concentration of Fenbendazole in the *Sample solution* (mg/mL)

Calculate the percentage of any other impurity in the portion of Fenbendazole taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any impurity from the *Sample solution*

$r_S$  = peak response of [USP Fenbendazole RS](#) from *Standard solution A*

$C_S$  = concentration of [USP Fenbendazole RS](#) in *Standard solution A* (mg/mL)

$C_U$  = concentration of Fenbendazole in the *Sample solution* (mg/mL)

**Acceptance criteria:** See [Table 2](#). The reporting level for impurities is 0.1%.

**Table 2**

| Name                            | Relative Retention Time | Acceptance Criteria, NMT (%) |
|---------------------------------|-------------------------|------------------------------|
| Fenbendazole related compound A | 0.25                    | 0.5                          |
| Fenbendazole related compound B | 0.65                    | 0.5                          |
| Fenbendazole                    | 1.0                     | —                            |
| Any individual impurity         | —                       | 0.5                          |
| Total impurities                | —                       | 1                            |

#### SPECIFIC TESTS

##### • [Loss on Drying \(731\)](#)

**Analysis:** Dry at 100°–105° for 3 h.

**Acceptance criteria:** NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed, light-resistant containers, and store at room temperature.
- **LABELING:** Label to indicate that it is for veterinary use only.
- **USP REFERENCE STANDARDS (11).**

[USP Fenbendazole RS](#)

[USP Fenbendazole Related Compound A RS](#)

Methyl (1*H*-benzimidazole-2-yl)carbamate.  
C<sub>9</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> 191.19

[USP Fenbendazole Related Compound B RS](#)

Methyl [5(6)-chlorobenzimidazole-2-yl]carbamate.  
C<sub>9</sub>H<sub>8</sub>ClN<sub>3</sub>O<sub>2</sub> 225.63

[USP Mebendazole RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact                                       | Expert Committee          |
|----------------|-----------------------------------------------|---------------------------|
| FENBENDAZOLE   | <a href="#">Documentary Standards Support</a> | SM32020 Small Molecules 3 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(6)

Current DocID: GUID-797D27B7-31A6-48AD-BA2E-77005938668D\_4\_en-US

DOI: [https://doi.org/10.31003/USPNE\\_M32672\\_04\\_01](https://doi.org/10.31003/USPNE_M32672_04_01)

DOI ref: [we9ul](#)

OFFICIAL